Agile Therapeutics (AGRX) Stock Boosted by Positive Clinical Data


Shares of Agile Therapeutics (AGRX) stock are up Monday morning after the company announced positive results from a study. Agile Therapeutics said that the trans-dermal contraceptive patch Twirla met its primary endpoint in the study by demonstrating non-inferior skin adhesion when compared to Xulane, the generic version of the Ortho Evra contraceptive patch. The wear study was recommended by the FDA’s Office of New Drugs as part of the company’s process in seeking regulatory approval.

AGRX stock is currently trading at $0.97 as of 10:08 AM on Monday, Feb 11, an increase of $0.07, or 8.43% from the previous closing price of $0.89. Volume today is elevated. So far 1,733,585 shares have traded compared to average volume of 190,402 shares. Agile Therapeutics stock has traded between $0.95 and $1.07 so far today.

Stock Score Report, InvestorsObserver’s proprietary scoring system gives AGRX stock a score of 58 out of a possible 100. That score is based on three component scores. A fundamental score of 71, a long-term technical score of 54 and a short-term technical score of 51.

Agile Therapeutics stock holds an analyst average recommendation of Moderate Buy, with a median target price of $3.13, which is 228.1% higher than the stock’s current trading price.

Our proprietary system combines short and long-term technical factors, Wall Street’s opinion, and other fundamental factors into an overall score that measures a stock’s suitability for investment.

The major indices are higher this morning. The NASDAQ has risen 0.21% to 7,313.74. The S&P 500 has gained 0.14% to 2,711.70. The Dow Jones Industrial Average is up 0.05% to 25,118.67.

Get More Analysis and Trade Ideas on Agile Therapeutics (AGRX) Stock

Symbols: AGRX

You May Also Like